Biogen to invest 1 billion Swiss francs for new Swiss biopharma plant

1 July 2015

US biotech giant Biogen (Nasdaq: BIIB) says it is investing 1 billion Swiss francs ($1.07 billion) in Luterbach in the Swiss canton of Solothurn in a new production plant.

Work would begin on the plant at the end of this year with completion set for the end of 2018. By 2019 the plant should be operational, creating 400 jobs and producing biopharmaceutical medicine, Biogen said at a press conference. The plant would be the fifth for the company in the world.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK